Daytime sleepiness in elderly Parkinson’s disease patients and treatment with the psychostimulant modafinil: A preliminary study

Daytime sleepiness in elderly Parkinson’s disease patients and treatment with the psychostimulant modafinil: A preliminary study

Johan LökkInstitution of Neurobiology, Caring Sciences, and Society, Karolinska Institute, Stockholm, SwedenBackground: Patients with Parkinson’s disease (PD) or Parkinsonian syndromes often report excessive daytime sleepiness (EDS). The aim of this study was to evaluate t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Johan Lökk
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2010
Materias:
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Acceso en línea:https://doaj.org/article/f954008905b44885a920f550c0298815
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f954008905b44885a920f550c0298815
record_format dspace
spelling oai:doaj.org-article:f954008905b44885a920f550c02988152021-12-02T06:52:21ZDaytime sleepiness in elderly Parkinson’s disease patients and treatment with the psychostimulant modafinil: A preliminary study1176-63281178-2021https://doaj.org/article/f954008905b44885a920f550c02988152010-03-01T00:00:00Zhttp://www.dovepress.com/daytime-sleepiness-in-elderly-parkinsonrsquos-disease-patients-and-tre-a4180https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Johan LökkInstitution of Neurobiology, Caring Sciences, and Society, Karolinska Institute, Stockholm, SwedenBackground: Patients with Parkinson’s disease (PD) or Parkinsonian syndromes often report excessive daytime sleepiness (EDS). The aim of this study was to evaluate the effects of the psychostimulant modafinil on elderly, institutionalized, severely impaired PD patients with EDS.Method: A three-week open study on ten institutionalized PD patients scoring >10 points on the Epworth Sleepiness Scale (ESS) with modafinil eventually on 100 mg twice a day. Patients were assessed at the start, week 1, and week 3 with ESS, Clinical Global Impression (CGI) scale severity of PD and appetite.Results: Reduction of ESS score and PD severity over time were found as well as a significant increase in appetite and reduction in CGI score.Conclusion: Modafinil 100 mg twice a day was safe and modestly effective for the treatment of EDS in elderly, institutionalized PD patients. Sustaining wakefulness throughout all stages of PD is crucial for participating in life, maintaining social life, and improving quality of life.Keywords: Parkinson’s disease, daytime sleepiness, Epworth sleepiness scale, psychostimulant Johan LökkDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Issue 1, Pp 93-97 (2010)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Johan Lökk
Daytime sleepiness in elderly Parkinson’s disease patients and treatment with the psychostimulant modafinil: A preliminary study
description Johan LökkInstitution of Neurobiology, Caring Sciences, and Society, Karolinska Institute, Stockholm, SwedenBackground: Patients with Parkinson’s disease (PD) or Parkinsonian syndromes often report excessive daytime sleepiness (EDS). The aim of this study was to evaluate the effects of the psychostimulant modafinil on elderly, institutionalized, severely impaired PD patients with EDS.Method: A three-week open study on ten institutionalized PD patients scoring >10 points on the Epworth Sleepiness Scale (ESS) with modafinil eventually on 100 mg twice a day. Patients were assessed at the start, week 1, and week 3 with ESS, Clinical Global Impression (CGI) scale severity of PD and appetite.Results: Reduction of ESS score and PD severity over time were found as well as a significant increase in appetite and reduction in CGI score.Conclusion: Modafinil 100 mg twice a day was safe and modestly effective for the treatment of EDS in elderly, institutionalized PD patients. Sustaining wakefulness throughout all stages of PD is crucial for participating in life, maintaining social life, and improving quality of life.Keywords: Parkinson’s disease, daytime sleepiness, Epworth sleepiness scale, psychostimulant
format article
author Johan Lökk
author_facet Johan Lökk
author_sort Johan Lökk
title Daytime sleepiness in elderly Parkinson’s disease patients and treatment with the psychostimulant modafinil: A preliminary study
title_short Daytime sleepiness in elderly Parkinson’s disease patients and treatment with the psychostimulant modafinil: A preliminary study
title_full Daytime sleepiness in elderly Parkinson’s disease patients and treatment with the psychostimulant modafinil: A preliminary study
title_fullStr Daytime sleepiness in elderly Parkinson’s disease patients and treatment with the psychostimulant modafinil: A preliminary study
title_full_unstemmed Daytime sleepiness in elderly Parkinson’s disease patients and treatment with the psychostimulant modafinil: A preliminary study
title_sort daytime sleepiness in elderly parkinson’s disease patients and treatment with the psychostimulant modafinil: a preliminary study
publisher Dove Medical Press
publishDate 2010
url https://doaj.org/article/f954008905b44885a920f550c0298815
work_keys_str_mv AT johanlampoumlkk daytimesleepinessinelderlyparkinsonamprsquosdiseasepatientsandtreatmentwiththepsychostimulantmodafinilapreliminarystudy
_version_ 1718399731302924288

Ejemplares similares